Blood sampling C1: Blood samples will be collected at four key time points :
* baseline (T1),
* first scan assessment (T2),
* second scan assessment (T3),
* and progression (T4).
Study summary
The circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. The potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. In the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
2. 18 years old or higher ?
3. Patient who has provided informed, written, and explicit consent,
4. Patient affiliated with a French Social Protection System.
In the case of a tumor biopsy:
5. Tumor considered as accessible by biopsy,
6. Normal hemostasis assessment (PT, APTT, platelets),
7. No anticoagulant or antiaggregant treatment for the biopsy.
Exclusion Criteria:
1. Pregnant woman and/or breast-feeding,
2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
3. Private persons of freedom or under guardianship,
4. Patient with a history of other invasive cancers within the 5 years preceding inclusion.
Primary outcome measure(s)
All Cohorts : Study of the feasibility of detecting and/or analysing blood or tissue tumour biomarkers. — 10 years Success rate of the detection technique used (the criterion will be detailed according to the biomarker evaluated, in each of the cohorts)
Trial sites (1)
Facility
City
Region
Status
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier
France
More Institut du Cancer de Montpellier - Val d'Aurelle trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
